{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-006546","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.242779+00:00","generated_at":"2026-06-05T03:20:23.505185+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CervoMed reports Phase 2a biomarker data: neflamapimod reduces GFAP, correlates with clinical outcomes in DLB","bullets":["In pure DLB patients, neflamapimod reduced GFAP by mean 10.6 pg/mL vs 14.1 increase with placebo (p=0.04).","GFAP reduction correlated with improvement on CDR-SB (r=0.542, p=0.036) in neflamapimod-treated pure DLB patients.","Preclinical data from UCL shows neflamapimod enhances axonal transport in tauopathy mouse model of FTD.","CEO states data support clinical efficacy in DLB and rationale for evaluating neflamapimod in frontotemporal dementia."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-006546","json":"https://secwatch.observer/filing/0001437749-24-006546.json","markdown":"https://secwatch.observer/filing/0001437749-24-006546.md","text":"https://secwatch.observer/filing/0001437749-24-006546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924006546/0001437749-24-006546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924006546/crvo20240304_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:20:23.505185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}